PDUFA date

In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application.[1] It is part of the regime established by the Prescription Drug User Fee Act to ensure funding of the Food and Drug Administration's drug approval activities in return for adhering to a largely fixed timetable of regulatory actions.

History

Prior to the Prescription Drug User Fee Act (PDUFA), median approval times of New Drug Applications ranged between 21 and 29 months.[2] The Prescription Drug User Fee Act was first passed in 1992 to facilitate the funding of the Food and Drug Administration while ensuring a more predictable timetable for drug approvals.[3] Under the PDUFA regime, New Drug Applications and Biologics License Applications (together referred to as 'human drug applications' in the PDUFA context) are levied a fee upon filing. As of 2021, this fee was US$2,875,842 for applications requiring clinical data and US$1,437,921 for applications that do not.[4] In return, the FDA strives to complete review of applications within 10 months for most applications and 6 months for priority reviews.[5] The PDUFA date thus serves as a 'best estimate' of when a decision on a New Drug Application or a Biologics License Application would be forthcoming. This response may be a decision to approve the application or a Complete Response Letter (CRL).

The PDUFA date may be extended by the Food and Drug Administration in certain circumstances.[6] These include circumstances such as a 'major amendment', e.g. where data submitted to a final study report is updated or data inadvertently omitted is supplied.[7]

The PDUFA must be reauthorized every five years. The current version, PDUFA VII, was reauthorized as part of the Food and Drug Administration Reauthorization Act (FDARA) signed on 30 September 2022.[8] The reauthorization will expire in September 2027.[9]

Relevance

The PDUFA date serves as a good first approximation of when a final decision on drug approval can be expected. Sponsors frequently publish PDUFA dates for their pending applications,[1] and while there is no official list of PDUFA dates,[10] several websites collect PDUFA dates from press announcements in a calendar form.[11]

References
  1. Speights, Keith (2016-07-07). "What Is a PDUFA Date?". The Motley Fool. Retrieved 2021-06-30.
  2. Office of the Commissioner, Center for Biologics Evaluation and Research. "User Fee Performance Reports - FY 1995 PDUFA Performance Report". wayback.archive-it.org. Archived from the original on 2017-04-06. Retrieved 2021-06-30.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  3. "PDUFA". www.phrma.org. Retrieved 2021-06-30.
  4. "Prescription Drug User Fee Rates for Fiscal Year 2021". Federal Register. 2020-08-03. Retrieved 2021-06-30.
  5. "GAO Analysis Says FDA is Meeting PDUFA Commitments". FDA Law Blog. 2020-04-09. Retrieved 2021-06-30.
  6. Center for Drug Evaluation and Research, Office of New Drugs. "Manual of Policies and Procedures (MAPP) 6010.8 Rev. 1: NDAs and BLAs: Communication to Applicants of Planned Review Timelines". FDA, Center for Drug Evaluation and Research. Retrieved 2021-06-30.
  7. "When Does FDA Extend a PDUFA Date? | Eye on FDA". eyeonfda.com. Retrieved 2021-06-30.
  8. Office of the Commissioner (2018-11-03). "FDA Reauthorization Act of 2017 (FDARA)". FDA. Retrieved 2021-06-30.
  9. Center for Drug Evaluation and Research (2021-06-10). "PDUFA VII: Fiscal Years 2023 – 2027". FDA.
  10. "What is PDUFA? | Eye on FDA". eyeonfda.com. Retrieved 2021-06-30.
  11. "FDA Calendar – FDA Tracker". Retrieved 2021-06-30.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.